Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human coagulation factor VIII Fc fusion protein prophylaxis in hemophilia A
CTR20210593Phase 3Completed
- Sponsor
- Kaifeng Pharmaceutical Group Co., Ltd
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Factor VIII in hemophilia A, sponsored by Kaifeng Pharmaceutical Group Co., Ltd. Started Mar 2021; status: completed.
02
Drugs
Factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20210593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210593.